Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma

a gene and gene technology, applied in the field of cancer diagnosis, prognosis, drug screening, and treatment, can solve the problems of carrying a correspondingly poor prognosis, and achieve the effects of increasing, decreasing or stable level of increasing, decreasing or stable level of said somatic mutation over time, and increasing, decreasing or stable level of expression over tim

Inactive Publication Date: 2012-08-09
DUKE UNIV +1
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, tumors of Grades II and III are malignant tumors that grow invasively, progress to higher-grade lesions, and carry a correspondingly poor prognosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
  • Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
  • Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

[0059]DNA was extracted from primary tumor and xenograft samples and patient-matched normal blood lymphocytes obtained from the Tissue Bank at the Preston Robert Tisch Brain Tumor Center at Duke and collaborating centers, as previously described17. All brain tumors analyzed were subjected to consensus review by two neuropathologists. The panel of brain tumors consisted of 21 pilocytic astrocytomas and 2 subependymal giant cell gliomas (WHO Grade I); 31 diffuse astrocytomas, 51 oligodendrogliomas, three oligoastrocytomas, 30 ependymomas, and seven pleomorphic xanthoastrocytomas (WHO Grade II); 43 anaplastic astrocytomas, 36 anaplastic oligodendrogliomas, and seven anaplastic oligoastrocytomas (WHO Grade III); 178 GBMs and 55 medulloblastomas (WHO Grade IV). The GBM samples included 165 primary and 13 secondary cases. Fifteen of the GBMs were from patients1 year after a prior diagnosis of a lower grade glioma (WHO Grades I-III). Sixty-six of the 178 GBMs, but none...

example 2

High Frequency Alterations of IDH1 in Young GBM Patients

[0062]The top CAN-gene list included a number of individual genes which had not previously been linked to GBMs. The most frequently mutated of these genes, IDH1, encodes isocitrate dehydrogenase 1, which catalyzes the oxidative carboxylation of isocitrate to α-ketoglutarate, resulting in the production of NADPH. Five isocitrate dehydrogenase genes are encoded in the human genome, with the products of three (IDH3 alpha, IDH3 beta, IDH3 gamma) forming a heterotetramer (α2βγ in the mitochondria and utilizing NAD(+) as an electron acceptor to catalyze the rate-limiting step of the tricarboxylic acid cycle. The fourth isocitrate dehydrogenase (IDH2) is also localized to the mitochondria, but like IDH1, uses NADP(+) as an electron acceptor. The IDH1 product, unlike the rest of the IDH proteins, is contained within the cytoplasm and peroxisomes (41). The protein forms an asymmetric homodimer (42), and is thought to function to regener...

example 3

Glioblastoma Multiforme (GBM) DNA Samples

[0065]Tumor DNA was obtained from GBM xenografts and primary tumors, with matched normal DNA for each case obtained from peripheral blood samples, as previously described (1). All samples were given the histologic diagnosis of glioblastoma multiforme (GBM; World Health Organization Grade IV), except for two Discovery Screen samples who were recorded as “high grade glioma, not otherwise specified”. Samples were classified as recurrent for patients in whom a GBM had been diagnosed at least 3 months prior to the surgery when the study GBM sample was obtained. There were 3 recurrent GBMs in the Discovery Screen, and 15 in the Prevalence Screen. Samples were classified as secondary for patients in whom a lower grade glioma (WHO grade I-III) had been histologically confirmed at least 1 year prior to the surgery when the study GBM sample was obtained. One Discovery Screen sample and 5 Prevalence Screen samples were classified as secondary.

[0066]Pert...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
crystal structureaaaaaaaaaa
hydrophilic interactionsaaaaaaaaaa
frequencyaaaaaaaaaa
Login to View More

Abstract

We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.

Description

[0001]This application was made using funds from the United States government. Therefore the U.S. government retains certain rights in the invention under the terms of NIH grants CA 43460, CA 57345, CA 62924, R01CA118822, NS20023-21, R37CA11898-34, and CA 121113.TECHNICAL FIELD OF THE INVENTION[0002]This invention is related to the area of cancer diagnostics, prognostics, drug screening, and therapeutics. In particular, it relates to brain tumors in general, and glioblastoma multiforme, in particular.BACKGROUND OF THE INVENTION[0003]Gliomas, the most common type of primary brain tumors, are classified as Grade I to Grade IV using histopathological and clinical criteria established by the World Health Organization (WHO)1. This group of tumors includes a number of specific histologies, the most common of which are astrocytomas, oligodendrogliomas, and ependymomas. Grade I gliomas, often considered to be benign lesions, are generally curable with complete surgical resection and rarely,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68C07K16/40C07H21/04G01N33/574
CPCC12Q1/6886C12Q2600/112C12Q2600/156C12Q2600/136C12Q2600/118A61P35/00A61P37/04G16B20/20G16B40/20
Inventor VOGELSTEIN, BERTKINZLER, KENNETH W.PARSONS, D. WILLIAMSZHANG, XIAOSONGLIN, JIMMY CHENG-HOLEARY, REBECCA J.ANGENENDT, PHILIPPPAPADOPOULOS, NICKOLASVELCULESCU, VICTORPARMIGIANI, GIOVANNIKARCHIN, RACHELJONES, SIANYAN, HAIBIGNER, DARELLKUAN, CHIEN-TSUNRIGGINS, GREGORY J.
Owner DUKE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com